

## UCI Medical Center Clinical Trials Web Page Standard Research Recruitment Advertisement Format

Note: This form must be submitted to the IRB for approval either as part of a new protocol application or with a request for modification to an IRB-approved protocol (electronic Protocol Modification (e-mod) Request can be found at [www.rgs.uci.edu/hs/mod](http://www.rgs.uci.edu/hs/mod)). When you have received approval from the IRB for the advertisement text, please provide a stamped copy to Leanne Spaide, UCI Medical Center, Marketing and Public Relations Department, Rt. 163A, fax (714) 456-8968, for posting on the [www.ucihealth.com](http://www.ucihealth.com) clinical trials Web page.

1. Lead Researcher: Sergei Grando, M.D., Ph.D., Dr.Sci.
2. Study Title: Proof -of-Concept Study of IVIg Efficacy in Patients with Cutaneous Lupus Erythematosus
3. Purpose of Study (e.g., to evaluate a new drug for breast cancer): The purpose of this research study is to find out more about intravenous immunoglobulin (IVIg) in people with cutaneous lupus erythematosus.
4. Eligibility (e.g., adults on medication for high blood pressure; diabetic patients on insulin; normal, healthy adults; etc.): Adults who have been diagnosed with cutaneous lupus erythematosus
5. Location (if other than UCIMC):  
University of California, Irvine Healthcare, Dermatology  
Gottschalk Medical Plaza  
1 Medical Plaza Drive, Irvine, CA 92697
6. Time Commitment (e.g., three one-hour long visits in three weeks): This study includes 10 visits and takes about 19 hours over a period of approximately 9 months.
7. Anticipated Benefits (if any): Taking part in this study may or may not make your health better. While researchers hope that IVIg will be better than the standard (usual) treatment, there is no proof of this yet. If IVIg therapy proves to treat your condition more effectively or with less side effects than the standard treatment, you may benefit from participating in the study, but this cannot be guaranteed
8. Compensation (if any): You will not be compensated for your participation in this study.
9. Contact Name, UCI Department, Phone Number and E-mail:

HS# 2013-9351

Approved by IRB on: 03/08/13

**IRB USE ONLY - DO NOT ALTER THIS FOOTER**



Sergei Grando, M.D., Ph.D., Dr.Sci.  
UCI Department of Dermatology  
949-824-2713  
bswasdib@uci.edu

Signature of Lead Researcher: \_\_\_\_\_ Date: \_\_\_\_\_

IRB Approval Granted on:

